1Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin, 2011, 61 : 69-90.
2Burd EM. Human papillomavirus and cervical cancer [ J ]. Clin Microbiol Rev, 2003, 16 : 1-17.
3Trope A, Sjoborg K, Esklld A, et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia[ J]. J Cliu Microbiol, 2009, 47 2458-2464.
4Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial [ J ]. Lancet Oncol, 2012, 13: 78-88.
5Cuzick J, Arbyn M, Sankaranaarayanan R, et at. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries [ J ]. Vaccine, 2008, 26 : K29-41.
6Franco EL, Cuzick J, Hildesheim A, et at. Chapter 20 : Issues in planning cervical cancer screening in the era of HPV vaccination [J]. Vaccine, 2006, 24 Suppl 3 : $3/171-177.
7Solomon D, Davey D, Kuman R, et at. The 2001 Bethesda System : terminology for reporting results of cervical cytology [ J 1- JAMA, 2002,287:2114-2119.
8Trop6 A, Sjcborg K, Eskild A, et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia [ J ]. J Clin Microbiol, 2009, 47: 2458-2464.
9Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1 : HPV in the etiology of human eancer[ J]. Vaccine, 2006, 24 $3/1-10.
10Benevolo M, Terrenato I, Mottolese M, et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC-2-positive patients [ J ]. Cancer Causes Control, 2011,22: 869-875.
